Literature DB >> 25057435

Role of SOX family of transcription factors in central nervous system tumors.

Arlet M Acanda de la Rocha1, Nicolas Sampron2, Marta M Alonso1, Ander Matheu3.   

Abstract

SOX genes are developmental regulators with functions in the instruction of cell fate and maintenance of progenitor's identity during embryogenesis. They play additional roles during tissue homeostasis and regeneration in adults particularly in the Central Nervous System (CNS). In the last years a growing number of evidences has shown that mutations and dysfunction of SOX factors are implicated in several human diseases, including a variety of cancers. In this review, we will summarize the current knowledge about SOX family in CNS tumors and their role in the origin and maintenance of the subpopulation of cancer stem cells in these tumors.

Entities:  

Keywords:  CNS tumors; SOX; cell of origin; glioblastoma; glioma stem cell; oncogenic SOX2; therapy target

Year:  2014        PMID： 25057435      PMCID： PMC4106650     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN： 2156-6976            Impact factor:   6.166


  111 in total

1.  A critical role for Sox9 in notch-induced astrogliogenesis and stem cell maintenance.

Authors:  Simone Martini; Kristina Bernoth; Heather Main; German Dario Camargo Ortega; Urban Lendahl; Ursula Just; Ralf Schwanbeck
Journal:  Stem Cells       Date:  2013-04       Impact factor: 6.277

Review 2.  Gli and hedgehog in cancer: tumours, embryos and stem cells.

Authors:  Ariel Ruiz i Altaba; Pilar Sánchez; Nadia Dahmane
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

3.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

Authors:  Alejandra Bruna; Rachel S Darken; Federico Rojo; Alberto Ocaña; Silvia Peñuelas; Alexandra Arias; Raquel Paris; Avelina Tortosa; Jaume Mora; Jose Baselga; Joan Seoane
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

4.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

5.  SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity.

Authors:  Rosaria Maria Rita Gangemi; Fabrizio Griffero; Daniela Marubbi; Marzia Perera; Maria Cristina Capra; Paolo Malatesta; Gian Luigi Ravetti; Gian Luigi Zona; Antonio Daga; Giorgio Corte
Journal:  Stem Cells       Date:  2009-01       Impact factor: 6.277

6.  Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma.

Authors:  Rebecca Favaro; Irene Appolloni; Serena Pellegatta; Alexandra Badiola Sanga; Pierfrancesco Pagella; Eleonora Gambini; Federica Pisati; Sergio Ottolenghi; Maria Foti; Gaetano Finocchiaro; Paolo Malatesta; Silvia K Nicolis
Journal:  Cancer Res       Date:  2014-03-05       Impact factor: 12.701

7.  Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines.

Authors:  F J Swartling; M Ferletta; M Kastemar; W A Weiss; B Westermark
Journal:  Oncogene       Date:  2009-06-22       Impact factor: 9.867

8.  Sox2 cooperates with Chd7 to regulate genes that are mutated in human syndromes.

Authors:  Erik Engelen; Umut Akinci; Jan Christian Bryne; Jun Hou; Cristina Gontan; Maaike Moen; Dorota Szumska; Christel Kockx; Wilfred van Ijcken; Dick H W Dekkers; Jeroen Demmers; Erik-Jan Rijkers; Shoumo Bhattacharya; Sjaak Philipsen; Larysa H Pevny; Frank G Grosveld; Robbert J Rottier; Boris Lenhard; Raymond A Poot
Journal:  Nat Genet       Date:  2011-05-01       Impact factor: 38.330

9.  miRNA-21 is developmentally regulated in mouse brain and is co-expressed with SOX2 in glioma.

Authors:  Jelena Põlajeva; Fredrik J Swartling; Yiwen Jiang; Umashankar Singh; Kristian Pietras; Lene Uhrbom; Bengt Westermark; Pernilla Roswall
Journal:  BMC Cancer       Date:  2012-08-29       Impact factor: 4.430

10.  Multipotent cell lineages in early mouse development depend on SOX2 function.

Authors:  Ariel A Avilion; Silvia K Nicolis; Larysa H Pevny; Lidia Perez; Nigel Vivian; Robin Lovell-Badge
Journal:  Genes Dev       Date:  2003-01-01       Impact factor: 11.361
View more
  41 in total

1.  G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells.

Authors:  Lijun Liu; Wojciech Michowski; Hiroyuki Inuzuka; Kouhei Shimizu; Naoe Taira Nihira; Joel M Chick; Na Li; Yan Geng; Alice Y Meng; Alban Ordureau; Aleksandra Kołodziejczyk; Keith L Ligon; Roderick T Bronson; Kornelia Polyak; J Wade Harper; Steven P Gygi; Wenyi Wei; Piotr Sicinski
Journal:  Nat Cell Biol       Date:  2017-02-13       Impact factor: 28.824

2.  Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients.

Authors:  James S Cordova; Hui-Kuo G Shu; Zhongxing Liang; Saumya S Gurbani; Lee A D Cooper; Chad A Holder; Jeffrey J Olson; Brad Kairdolf; Eduard Schreibmann; Stewart G Neill; Constantinos G Hadjipanayis; Hyunsuk Shim
Journal:  Neuro Oncol       Date:  2016-03-15       Impact factor: 12.300

3.  A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo.

Authors:  Christopher G Hubert; Maricruz Rivera; Lisa C Spangler; Qiulian Wu; Stephen C Mack; Briana C Prager; Marta Couce; Roger E McLendon; Andrew E Sloan; Jeremy N Rich
Journal:  Cancer Res       Date:  2016-02-19       Impact factor: 12.701

4.  Prognostic significance of SOX-1 expression in human hepatocelluar cancer.

Authors:  Jinshu Lou; Kai Zhang; Jing Chen; Yanping Gao; Rui Wang; Long-Bang Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

5.  SOX2 and SOX12 are predictive of prognosis in patients with clear cell renal cell carcinoma.

Authors:  Weijie Gu; Beihe Wang; Fangning Wan; Junlong Wu; Xiaolin Lu; Hongkai Wang; Yao Zhu; Hailiang Zhang; Guohai Shi; Bo Dai; Dingwei Ye
Journal:  Oncol Lett       Date:  2018-01-19       Impact factor: 2.967

6.  Clinicopathological evaluation of Sox10 expression in diffuse-type gastric adenocarcinoma.

Authors:  Marin Kato; Hiroshi Nishihara; Hideyuki Hayashi; Taichi Kimura; Yusuke Ishida; Lei Wang; Masumi Tsuda; Mishie Ann Tanino; Shinya Tanaka
Journal:  Med Oncol       Date:  2016-12-10       Impact factor: 3.064

7.  Decreased expression of SOX9 indicates a better prognosis and inhibits the growth of glioma cells by inducing cell cycle arrest.

Authors:  Jing Gao; Jia-Yi Zhang; Yu-Hong Li; Fu Ren
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 8.  Paradoxical role of SOX2 in gastric cancer.

Authors:  Estefania Carrasco-Garcia; Juliana C Santos; Idoia Garcia; Mitsue Brianti; Mikel García-Puga; José Pedrazzoli; Ander Matheu; Marcelo L Ribeiro
Journal:  Am J Cancer Res       Date:  2016-03-15       Impact factor: 6.166

9.  Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple-negative breast carcinoma.

Authors:  Aparna Harbhajanka; Satyapal Chahar; Kristy Miskimen; Paula Silverman; Lyndsay Harris; Nicole Williams; Vinay Varadan; Hannah Gilmore
Journal:  Hum Pathol       Date:  2018-06-09       Impact factor: 3.466

10.  SOX3 can promote the malignant behavior of glioblastoma cells.

Authors:  Jelena Marjanovic Vicentic; Danijela Drakulic; Idoia Garcia; Vladanka Vukovic; Paula Aldaz; Nela Puskas; Igor Nikolic; Goran Tasic; Savo Raicevic; Laura Garros-Regulez; Nicolas Sampron; Michael J Atkinson; Natasa Anastasov; Ander Matheu; Milena Stevanovic
Journal:  Cell Oncol (Dordr)       Date:  2018-09-12       Impact factor: 7.051
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.